STOCK TITAN
  1. Home
  2. Sec-filings
  3. JAZZ
  4. [Form 4] Jazz Pharmaceuticals plc Insider Trading Activity

Director at Jazz Pharmaceuticals (JAZZ) exercises 3,415 stock options

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Seamus Mulligan exercised a non-qualified stock option to acquire 3,415 Ordinary Shares at $138.08 per share. After this exercise, he holds 1,183,028 Ordinary Shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.

The option was originally granted on August 11, 2016 and had fully vested by August 1, 2017. Following this transaction, no shares remain under the exercised option, and there is no remaining derivative position reported in this filing.

Positive

  • None.

Negative

  • None.
Insider Mulligan Seamus
Role null
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (right to buy) 3,415 $0.00 --
Exercise Ordinary Shares 3,415 $138.08 $472K
holding Ordinary Shares -- -- --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 shares (Direct, null); Ordinary Shares — 1,183,028 shares (Direct, null); Ordinary Shares — 101,621 shares (Indirect, By Nerano Pharma Lim)
Footnotes (1)
  1. Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. This non-qualified stock option was granted on August 11, 2016 and vested over the period from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017.
Shares acquired via option exercise 3,415 shares Non-qualified stock option exercised on May 28, 2026
Option exercise price $138.08 per share Non-qualified stock option for Ordinary Shares
Direct holdings after transaction 1,183,028 shares Ordinary Shares held directly after May 28, 2026 exercise
Indirect holdings via Nerano Pharma Limited 101,621 shares Ordinary Shares beneficially owned through family entity
Exercised option shares remaining 0 shares Non-qualified stock option position after exercise
Derivative exercises in filing 1 transaction, 3,415 shares Form 4 transaction summary exerciseCount and exerciseShares
Non-Qualified Stock Option (right to buy) financial
"security_title: "Non-Qualified Stock Option (right to buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficially owned financial
"Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
indirect financial
"ownership_type: "indirect" and nature_of_ownership: "By Nerano Pharma Lim""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mulligan Seamus
(Last)(First)(Middle)
5TH FL, WATERLOO EXCHANGE
WATERLOO RD
(Street)
DUBLIN 4
(City)(State)(Zip)
IRELAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares05/28/2026M3,415A$138.081,183,028D
Ordinary Shares101,621IBy Nerano Pharma Lim(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$138.0805/28/2026M3,415 (2)08/10/2026Ordinary Shares3,415$0.00D
Explanation of Responses:
1. Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.
2. This non-qualified stock option was granted on August 11, 2016 and vested over the period from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017.
By: /s/Paz Dizon, as attorney in fact For: Seamus Mulligan06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did JAZZ director Seamus Mulligan report?

Director Seamus Mulligan reported exercising a non-qualified stock option to acquire 3,415 Jazz Pharmaceuticals Ordinary Shares at $138.08 per share. This is a compensation-related derivative exercise, not an open-market purchase or sale, and increases his directly held share count.

How many Jazz Pharmaceuticals (JAZZ) shares does Seamus Mulligan now hold?

After the reported transactions, Seamus Mulligan holds 1,183,028 Jazz Pharmaceuticals Ordinary Shares directly. He also beneficially owns 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family, according to the filing footnote.

What was the price on the JAZZ stock option exercised by Seamus Mulligan?

The non-qualified stock option exercised by Seamus Mulligan had an exercise price of $138.08 per Jazz Pharmaceuticals Ordinary Share. He exercised options for 3,415 shares, converting this derivative award into directly held equity as reflected in the Form 4 filing data.

Did the JAZZ director sell any shares in this Form 4 filing?

The Form 4 shows no open-market sales by Seamus Mulligan. It reports an exercise of a non-qualified stock option for 3,415 shares and a holding entry, with zero sell transactions listed, indicating the activity is limited to option exercise and updated ownership.

What is Nerano Pharma Limited’s role in Seamus Mulligan’s JAZZ holdings?

Nerano Pharma Limited holds 101,621 Jazz Pharmaceuticals shares beneficially owned by Seamus Mulligan and his immediate family. The filing notes this entity is owned and controlled by them, so these shares are reported as indirect ownership attributable to Mulligan on the Form 4.

Were the exercised JAZZ stock options already fully vested?

Yes. The footnote explains the non-qualified stock option was granted on August 11, 2016 and vested from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017, before Mulligan exercised 3,415 shares in this filing.